Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.39 Insider Own21.30% Shs Outstand84.88M Perf Week-8.27%
Market Cap480.94M Forward P/E- EPS next Y-1.49 Insider Trans-0.42% Shs Float75.86M Perf Month3.74%
Income-120.61M PEG- EPS next Q-0.51 Inst Own75.51% Short Float10.34% Perf Quarter-22.99%
Sales96.41M P/S4.99 EPS this Y-27.10% Inst Trans0.70% Short Ratio13.03 Perf Half Y3.10%
Book/sh1.86 P/B2.69 EPS next Y24.62% ROA-17.43% Short Interest7.84M Perf Year-34.69%
Cash/sh5.83 P/C0.86 EPS next 5Y-10.70% ROE-66.65% 52W Range3.66 - 9.06 Perf YTD-37.47%
Dividend Est.- P/FCF- EPS past 5Y-15.76% ROI-58.01% 52W High-44.95% Beta0.78
Dividend TTM- Quick Ratio3.53 Sales past 5Y158.96% Gross Margin90.63% 52W Low36.34% ATR (14)0.31
Dividend Ex-Date- Current Ratio3.53 EPS Y/Y TTM14.46% Oper. Margin-150.75% RSI (14)38.17 Volatility5.59% 5.97%
Employees244 Debt/Eq0.21 Sales Y/Y TTM-23.30% Profit Margin-125.11% Recom1.82 Target Price13.75
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q30.30% Payout- Rel Volume0.43 Prev Close5.26
Sales Surprise6.98% EPS Surprise25.21% Sales Q/Q-3.96% EarningsMay 08 AMC Avg Volume602.01K Price4.99
SMA20-6.43% SMA50-10.79% SMA200-18.28% Trades Volume259,980 Change-5.13%
Date Action Analyst Rating Change Price Target Change
Dec-14-23Upgrade Stifel Hold → Buy $8 → $15
Dec-12-23Initiated Deutsche Bank Buy $12
Sep-25-23Initiated Goldman Sell $4
Sep-22-23Initiated Cantor Fitzgerald Overweight $13
Jan-06-23Downgrade BofA Securities Buy → Neutral $24 → $12
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $27 → $13
Jul-07-22Initiated Mizuho Buy $15
Apr-13-22Initiated Goldman Sell $9
Mar-08-22Downgrade Stifel Buy → Hold $32 → $18
Sep-27-21Initiated William Blair Outperform
May-09-24 07:00AM
May-08-24 11:55PM
10:02AM Loading…
Apr-25-24 10:02AM
Feb-28-24 02:02PM
Feb-27-24 04:46PM
Feb-20-24 04:05PM
Feb-08-24 07:00AM
06:48AM Loading…
Feb-07-24 07:00AM
Jan-25-24 12:00PM
Jan-23-24 07:32AM
Jan-19-24 09:20AM
Jan-17-24 08:54AM
Jan-16-24 04:01PM
Jan-08-24 01:25PM
Dec-05-23 09:55AM
Nov-28-23 07:00AM
Nov-14-23 09:35AM
Nov-08-23 07:00AM
Nov-07-23 06:02PM
07:00AM Loading…
Oct-27-23 07:00AM
Sep-14-23 01:12AM
Sep-08-23 12:10PM
Sep-07-23 07:00AM
Aug-31-23 07:00AM
Aug-10-23 09:55AM
Aug-03-23 05:45PM
Jul-27-23 08:30AM
Jul-13-23 01:29PM
Jun-06-23 07:00AM
Jun-01-23 07:29AM
May-09-23 09:55AM
May-05-23 06:31AM
May-04-23 07:35PM
May-02-23 07:00AM
May-01-23 10:01AM
Apr-27-23 10:03AM
Apr-13-23 12:59PM
Mar-01-23 04:05PM
Feb-28-23 04:05PM
Feb-20-23 10:00AM
Feb-17-23 06:01AM
Feb-16-23 10:01AM
Dec-21-22 05:01AM
Dec-08-22 04:30PM
Nov-29-22 11:05AM
Nov-10-22 05:13AM
Nov-08-22 07:45PM
Nov-07-22 07:00AM
Nov-04-22 11:05AM
Nov-03-22 04:30PM
Oct-13-22 08:00AM
Oct-06-22 04:30PM
Sep-12-22 07:00AM
Sep-07-22 07:00AM
Aug-09-22 09:55AM
Aug-06-22 08:33AM
Aug-04-22 07:15PM
Jul-08-22 10:54AM
Jul-07-22 05:59PM
Jun-08-22 07:00AM
May-28-22 08:20AM
May-27-22 04:30PM
May-05-22 06:25PM
May-04-22 07:00AM
May-02-22 07:47AM
Apr-27-22 03:03PM
Mar-29-22 04:05PM
Mar-15-22 12:04PM
Mar-09-22 07:00AM
Mar-08-22 07:00AM
Mar-01-22 04:30PM
Feb-24-22 06:50PM
Feb-17-22 03:02PM
Feb-14-22 04:30AM
Feb-07-22 08:30AM
Feb-01-22 11:13AM
Jan-11-22 01:30AM
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenthal ArnonChief Executive OfficerMar 04 '24Sale6.9218,837130,3862,000,380Mar 05 06:00 PM
Kenkare-Mitra SaraPresident and Head of R&DMar 04 '24Sale6.9210,16970,387318,847Mar 05 06:00 PM
Romano GaryChief Medical OfficerMar 04 '24Sale6.926,00141,554196,313Mar 05 06:00 PM
GRASSO MARCChief Financial OfficerMar 04 '24Sale6.925,71639,562144,957Mar 05 06:00 PM
Rosenthal ArnonChief Executive OfficerDec 04 '23Sale5.5623,831132,5002,019,217Dec 06 06:30 PM
Kenkare-Mitra SaraPresident and Head of R&DDec 04 '23Sale5.5612,51969,606329,016Dec 06 06:30 PM
Romano GaryChief Medical OfficerDec 04 '23Sale5.565,03527,995202,314Dec 06 06:30 PM
GRASSO MARCChief Financial OfficerDec 04 '23Sale5.564,57425,431150,673Dec 06 06:30 PM
Polaris Venture Management Co.10% OwnerSep 11 '23Sale6.00500,0003,000,00010,853,817Sep 13 04:33 PM
MCGUIRE TERRANCEDirectorSep 11 '23Sale6.00500,0003,000,00010,853,817Sep 13 04:29 PM
Kenkare-Mitra SaraPresident and Head of R&DSep 05 '23Sale5.196,21432,277177,935Sep 06 07:17 PM
Rosenthal ArnonChief Executive OfficerSep 05 '23Sale5.195,64729,3331,645,448Sep 06 07:18 PM
Romano GaryChief Medical OfficerSep 05 '23Sale5.192,77114,39399,349Sep 06 07:16 PM
GRASSO MARCChief Financial OfficerSep 05 '23Sale5.191,1145,78632,247Sep 06 07:14 PM
Rosenthal ArnonChief Executive OfficerJun 02 '23Sale6.905,25536,2791,651,095Jun 05 06:48 PM
Kenkare-Mitra SaraPresident and Head of R&DJun 02 '23Sale6.904,09228,250184,149Jun 05 06:54 PM
Romano GaryChief Medical OfficerJun 02 '23Sale6.902,61718,067102,120Jun 05 06:50 PM
GRASSO MARCChief Financial OfficerJun 02 '23Sale6.901,0507,24933,361Jun 05 06:52 PM